ArticleProbiotics and antimicrobial proteins2026
Novel Anti-Microbial Peptides Design and Screening Against the KatG Using Molecular Docking and MD Simulation.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tuberculosis (TB) continues to be a significant worldwide health issue, with the rise of drug-resistant forms presenting substantial obstacles to successful treatment. The Mycobacterium tuberculosis (Mtb) enzyme catalase-peroxidase G (KatG) is a crucial molecular determinant of resistance, as it is necessary for the activation of isoniazid and for safeguarding the bacteria against oxidative stress. Mutations in KatG are a key mechanism of isoniazid resistance, contributing to the development of multidrug-resistant tuberculosis, hence establishing KatG as a crucial protein target for novel therapeutic approaches. This study focused on KatG to identify novel antimicrobial peptides (AMP) which were designed using rational changes of the host-defence peptide LL-37 to improve their efficacy against M. tuberculosis. A library of 15 antimicrobial peptides was designed using LL-37 modifications and categorized into three classes: Class I, Class II, and Class III. Peptide structures were predicted and docked against KatG resulting in top antimicrobial peptides. Molecular docking identified three top peptides P3 (-235.28 binding score), A5ζ (-229.42), and A4η (-233.81), with strong binding affinity with KatG active site residues. Further, molecular dynamic (MD) simulation was performed for 100 ns on these top three protein-peptide complexes. MD simulation showed distinct stability profiles majorly with P3 showing exceptional conformational stability. Additionally, safety assessment verified no-toxic, non-allergenic, favorable physicochemical and ADME properties. The computationally designed antimicrobial peptides (P3, A5ζ, and A4η) demonstrated strong binding affinity toward KatG. These interactions suggest their potential to interfere with key mycobacterial enzymatic functions and may contribute to strategies aimed at addressing existing drug resistance mechanisms.
Indexed as
Identifiers
42319666What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.